acidic nuclear phosphoprotein 32 family member B pseudogene 2Genealiases: []
Q-omics provides the consensus-scored ANP32BP2 profile across patient tissues and cancer cell-line models. ANP32BP2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, ANP32BP2 is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, ANP32BP2 RNA expression shows 6,486 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight TGCT, BLCA, and STAD as cancer lineages where ANP32BP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANP32BP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANP32BP2 survival associations across molecular data types. ANP32BP2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANP32BP2 RNA expression–survival associations across cancer types. High ANP32BP2 expression shows unfavorable associations in TGCT, LIHC, LUAD, LUSC and OV, but favorable associations in CHOL. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for ANP32BP2 RNA expression.
This table summarizes ANP32BP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ANP32BP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANP32BP2 shows lower tumor expression in BLCA and BRCA and higher tumor expression in HNSC and KIRC. The BLCA box plot shows higher ANP32BP2 RNA expression in normal versus tumor tissue (log2 FC = −0.112, t-test p = .003).
This table shows molecular features associated with ANP32BP2 in patient tissues and cancer cell lines. In patient samples, ANP32BP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
